胸腔內科

Medicine & Life Sciences

1. Taiwan 100%
2. Tuberculosis 85%
3. Lung 66%
4. Particulate Matter 59%
5. Chronic Obstructive Pulmonary Disease 48%
6. Multidrug-Resistant Tuberculosis 43%
7. Lung Neoplasms 38%
8. Connective Tissue Growth Factor 37%
9. Non-Small Cell Lung Carcinoma 37%
10. Asthma 36%
11. Cohort Studies 34%
12. ErbB Receptors 33%
13. Air Pollution 32%
14. Adenocarcinoma of Lung 30%
15. Pulmonary Tuberculosis 28%
16. Thrombin 27%
17. Protein-Tyrosine Kinases 25%
18. Transcription Factor AP-1 24%
19. Pneumonia 23%
20. Fibroblasts 23%
21. Interleukin-8 23%
22. Mycobacterium tuberculosis 23%
23. Epithelial Cells 22%
24. Therapeutics 22%
25. Population 21%
26. Inflammation 20%
27. Cyclooxygenase 2 20%
28. Polycyclic Aromatic Hydrocarbons 18%
29. Plasminogen Activator Inhibitor 1 18%
30. Mutation 18%
31. Neoplasms 17%
32. Pharmaceutical Preparations 17%
33. Obstructive Sleep Apnea 17%
34. Nanoparticles 17%
35. Phosphorylation 17%
36. A549 Cells 16%
37. Meta-Analysis 16%
38. Apoptosis 16%
39. Macrophages 16%
40. Pleural Effusion 16%
41. Fibrosis 15%
42. Vehicle Emissions 15%
43. Confidence Intervals 15%
44. Proteins 15%
45. Soot 14%
46. Zinc Oxide 14%
47. Sleep 13%
48. Interleukin-6 13%
49. Phosphotransferases 13%
50. Machine Learning 12%
51. Heart Rate 12%
52. Survival 12%
53. Coronavirus 12%
54. Small Interfering RNA 12%
55. Fluoroquinolones 12%
56. Hong Kong 12%
57. Odds Ratio 12%
58. Extracellular Signal-Regulated MAP Kinases 12%
59. Peptidoglycan 12%
60. Occupational Groups 12%
61. Metals 12%
62. Systemic Lupus Erythematosus 11%
63. China 11%
64. Rifampin 11%
65. Carbon 11%
66. Systematic Reviews 11%
67. Luciferases 11%
68. Endothelin-1 11%
69. Autophagy 11%
70. Biomarkers 11%
71. Phosphatidylinositol 3-Kinase 10%
72. Ovalbumin 10%
73. Neoplasm Metastasis 10%
74. Incidence 10%
75. Transforming Growth Factors 10%
76. National Health Programs 10%
77. Platelet Activation 10%
78. Mortality 10%
79. Complement Factor B 10%
80. Intensive Care Units 9%
81. Disintegrins 9%
82. CCAAT-Enhancer-Binding Proteins 9%
83. Tumor Necrosis Factor-alpha 9%
84. butylidenephthalide 9%
85. Drug Therapy 9%
86. Single-Chain Antibodies 9%
87. Rheumatoid Arthritis 9%
88. Malignant Pleural Effusion 9%
89. Diabetes Mellitus 9%
90. Drug Resistance 9%
91. p38 Mitogen-Activated Protein Kinases 9%
92. Toxicology 9%
93. Cell Survival 8%
94. Cytokines 8%
95. Welding 8%
96. Adrenal Cortex Hormones 8%
97. durvalumab 8%
98. Annexin A1 8%
99. Blood Platelets 8%